Cargando…
Pulsed Erlotinib as Sole Treatment of Leptomeningeal Carcinomatosis: Can We Avoid the Use of Intrathecal Therapy?
Leptomeningeal carcinomatosis, a not uncommon complication of non-small cell lung cancer, is associated with poor prognosis, and median survival is reported in case series as weeks to months. The advent of targeted therapy may have positively impacted the prognosis of such patients recently. Standar...
Autores principales: | Santhosh-Kumar, Cheruppolil R., Gray, Deborah, Fisher, Dave J. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elmer Press
2014
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5649775/ https://www.ncbi.nlm.nih.gov/pubmed/29147411 http://dx.doi.org/10.14740/wjon859w |
Ejemplares similares
-
Intrathecal Trastuzumab Treatment in Patients with Breast Cancer and Leptomeningeal Carcinomatosis
por: Park, Won-Young, et al.
Publicado: (2016) -
Gefitinib successfully administered in a lung cancer patient with leptomeningeal carcinomatosis after erlotinib-induced pneumatosis intestinalis
por: Uruga, Hironori, et al.
Publicado: (2018) -
Intrathecal trastuzumab for leptomeningeal carcinomatosis in patients with human epidermal growth factor receptor 2 positive breast cancer
por: Gulia, Seema, et al.
Publicado: (2016) -
SDPS-16 CYTOLOGIC AND SEROLOGIC RESPONSE WITH INTRATHECAL METHOTREXATE IN A PATIENT WITH LEPTOMENINGEAL CARCINOMATOSIS FROM OVARIAN CANCER
por: Cordova, Christine, et al.
Publicado: (2023) -
Recent Advancements of Treatment for Leptomeningeal Carcinomatosis
por: Gwak, Ho-Shin, et al.
Publicado: (2015)